Management of pregnancy in hereditary angioedema

• Authors: Marta Sánchez-Jareño , Rosario Cabañas , Teresa Caballero

Title variants

PL

Postępowanie w ciąży u chorej z wrodzonym obrzękiem naczynioruchowym

• Languages of publication: EN PL

Abstracts

EN

Hereditary angioedema due to C1-inhibitor deficiency (HAE) is a rare disease. HAE course can be more severe in female patients due to the activation of contact system by endogen oestrogens. Pregnancy can therefore worsen the disease course in some cases and the HAE management during pregnancy is often a challenge because of the limitation in treatment options. Plasma derived C1 inhibitor concentrate is the election drug for the treatment of acute attacks, short term prophylaxis and long term prophylaxis. In this review we will update the potential variations in HAE clinical course and the indications of the currently available treatments during pregnancy, delivery and breastfeeding.

PL

Wrodzony obrzęk naczynioruchowy z niedoboru C1-inhibitora (HAE) jest chorobą rzadką. U kobiet przebieg HAE może być cięższy z powodu aktywacji przez endogenne estrogeny szlaku zależnego od czynnika kontaktu. Dlatego w części przypadków ciąża może pogarszać przebieg schorzenia, a kontrola objawów HAE podczas ciąży jest często trudna z powodu ograniczeń w możliwych opcjach terapeutycznych. Koncentrat osoczopochodnego C1-inhibitora jest lekiem z wyboru w ostrych napadach oraz profilaktyce krótko- i długoterminowej. W niniejszej pracy dokonano przeglądu aktualnej wiedzy o możliwych zmiennościach w przebiegu klinicznym i wskazaniach obecnie dostępnych w HAE leków w okresie ciąży, porodu i karmienia piersią.

Keywords

EN

C1-inhibitor; Hereditary angioedema; breast-feeding; delivery; pregnancy; treatment

Discipline

• MEDICINE: MEDICINE

• Publisher: Oficyna Wydawnicza Mediton
• Journal: Alergia Astma Immunologia - przegląd kliniczny
• Year: 2018
• Volume: 23
• Issue: 4
• Pages: 186-192

Contributors

author

Marta Sánchez-Jareño

• Hospital La Paz Institute for Health Research, (IdiPaz), Madrid, Spain

author

Rosario Cabañas

• Hospital La Paz Institute for Health Research, (IdiPaz), Madrid, Spain

author

Teresa Caballero

• Hospital La Paz Institute for Health Research, (IdiPaz), Madrid, Spain, Biomedical Research Network on Rare Diseases-U754 (CIBERER), Madrid, Spain

References

• 1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-16.
• 2. Caballero T, Baeza ML, Cabañas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 2011; 21: 333-47; quiz follow 347. Erratum in: J Investig Allergol Clin Immunol 2012; 22: 3 p following 153.
• 3. Cicardi M, Zuraw BL. Angioedema Due to Bradykinin Dysregulation. J Allergy Clin Immunol Pract 2018; 6: 1132-41.
• 4. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129: 308-20.
• 5. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-74.
• 6. Steiner UC, Weber-Chrysochoou C, Helbling A, et al. Hereditary angioedema due to C1 -inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study. Orphanet J Rare Dis 2016; 11: 43.
• 7. Banerji A, Riedl M. Managing the female patient with hereditary angioedema. Women’s Health 2016; 12: 351-61.
• 8. Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008; 199: 484.e1-4.
• 9. Xu YY1, Jiang Y, Zhi YX, et al. Clinical features of hereditary angioedema in Chinese patients: new findings and differences from other populations. Eur J Dermatol 2013; 23: 500-4.
• 10. Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol 2010; 6: 17.
• 11. Geng B, Riedl MA. HAE update: special considerations in the female patient with hereditary angioedema. Allergy Asthma Proc 2013; 34: 13-8.
• 12. Caballero T, Canabal J, Rivero-Paparoni D, Cabañas R. Management of hereditary angioedema in pregnant women: a review. Int J Womens Health 2014; 6: 839-48.
• 13. Caballero T, Baeza ML, Cabañas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol 2011; 21: 422-41. Erratum in: J Investig Allergol Clin Immunol 2012; 22: 3 p following 153.
• 14. Chinniah N, Katelaris CH. Hereditary angioedema and pregnancy. Aust N Z J Obstet Gynaecol 2009; 49: 2-5.
• 15. Czaller I, Visy B, Csuka D, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 2010; 152: 44-9.
• 16. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010; 203: 131.e1-7.
• 17. González-Quevedo T, Larco JI, Marcos C, et al. Management of Pregnancy and Delivery in Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. J Investig Allergol Clin Immunol 2016; 26: 161-7.
• 18. Machado AM, Pires RM, Martins RO, Grumach AS. Pregnancy and Postpartum in Hereditary Angioedema With C1 Inhibitor Deficit in Women Who Have No Access to Therapy. J Investig Allergol Clin Immunol 2017; 27: 322-3.
• 19. Hakl R, Kuklínek P, Krčmová I, et al. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy. J Clin Immunol 2018; 38(7):810-15.
• 20. Caballero T, Maurer M, Longhurst HJ, et al. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. J Investig Allergol Clin Immunol 2016; 26: 383-6.
• 21. McGlinchey PG, Golchin K, McCluskey DR. Life-threatening laryngeal oedema in a pregnant woman with hereditary angioedema. Ulster Med J 2000; 69: 54-7.
• 22. Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35: 184-7.
• 23. Farkas H, Csuka D, Tóth F, et al. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. Eur J Obstet Gynecol Reprod Biol 2012; 165: 366-7.
• 24. Postnikoff IM, Pritzker KP. Hereditary angioneurotic edema: an unusual case of maternal mortality. J Forensic Sci 1979; 24: 473-8.
• 25. Visy B, Füst G, Varga L, et al. Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol (Oxf) 2004; 60: 508-15.
• 26. Longhurst H, Cicardi M, Craig T, et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med 2017; 376:1131-40.
• 27. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/ EAACI guideline for the management of hereditary angioedema - The 2017 revision and update. Allergy 2018; 73: 1575-96.
• 28. Ruconest®, Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/ruconest-epar-product-information_en.pdf Access 13th October 2018.
• 29. Firazyr®, Summary of Product Characteristics. Available at: https:// www.ema.europa.eu/documents/product-information/firazyr-epar-product-information_en.pdf Accessed 13th October 2018.
• 30. Ecallantide (Kalbitor®) approval history. Available at: https://www. drugs.com/history/kalbitor.html Accessed 14th October 2018.
• 31. Banerji A, Busse P, Shennak M, et al. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. N Engl J Med 2017; 376: 717- 28.
• 32. FDA approves new treatment for rare hereditary disease. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm618261.html Accessed 13th October 2018.
• 33. Fox J, Vegh AB, Martinez-Saguer I, et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc 2017; 38: 216-21.
• 34. Berinert® prescribing information. Available at: http://labeling. cslbehring.com/PI/US/Berinert/EN/Berinert-Prescribing-Information. pdf Accessed 13th October 2018.
• 35. Cinryze®, Summary of Product Characteristics. Available at: https:// www.ema.europa.eu/documents/product-information/cinryze-epar-product-information_en.pdf Accessed 13th October 2018.
• 36. HAEGARDA® prescribing information. Available at: http://labeling. cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf Accessed 13th October 2018
• 37. C1 esterase inhibitor (human) Pregnancy and Breastfeeding Warnings. Available at: https://www.drugs.com/pregnancy/c1-esterase- -inhibitor-human.html Accessed 13th October 2018.
• 38. Duvvur S, Khan F, Powell K. Hereditary angioedema and pregnancy. J Matern Fetal Neonatal Med 2007; 20: 563-5.
• 39. Hermans C. Successful management with C1-inhibitor concentrate of hereditary angioedema attacks during two successive pregnancies: a case report. Arch Gynecol Obstet 2007; 276: 271-6.
• 40. Farkas H, Jakab K, Temesszentandrási F, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120: 941-7.
• 41. Gorman PJ. Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate. Can Fam Physician 2008; 54: 365-6.
• 42. Baker JW, Craig TJ, Riedl MA, et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc 2013; 34: 162-9.
• 43. Chan W, Berlin N, Sussman GL. Management of hereditary angioedema with C1-inhibitor concentrate during two successive pregnancies. Int J Gynaecol Obstet 2013; 120: 189-90.
• 44. Satomura A, Fujita T, Nakayama T. Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema. Intern Med 2018; 57: 751-5.
• 45. FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease. Available at: https://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm564332.htm Accessed 14th October 2018.
• 46. Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970; 49: 241-2.
• 47. Boufleur K, Delcaro L, Cordeiro DL, et al. Successful and safe use of icatibant for life-threatening angioedema ttack during pregnancy in a patient with hereditary angioedema type I. J Allergy Clin Immun 2014; 133: AB36 (Abstract).
• 48. Zanichelli A, Mansi M, Periti G. Icatibant Exposure During Pregnancy in a Patient With Hereditary Angioedema. J Investig Allergy Clin Immunol 2015; 25: 447-9.
• 49. Farkas H, Kőhalmi KV, Veszeli N, et al. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res 2016; 42: 1026-8.
• 50. Kaminsky LW, Kelbel T, Ansary F, Craig T. Multiple doses of icatibant used during pregnancy. Allergy Rhinol (Providence) 2017; 8: 178- 81.
• 51. Moldovan D, Bernstein JA, Hakl R, Relan A. Safety of Recombinant Human C1 Esterase Inhibitor for Hereditary Angioedema Attacks in Pregnant Women. J Allergy Clin Immunol 2018; 141: AB53 (Abstract).
• 52. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-7.
• 53. Jurado-Palomo J, Muñoz-Caro JM, López-Serrano MC, et al. Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol 2013; 23: 1-6.
• 54. Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor--a long-term survey. Allergy 2012; 67: 1586-93.
• 55. Aygören-Pürsün E, Martinez Saguer I, Kreuz W, et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II - the natural history. Allergy 2013; 68: 1034-9.
• 56. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. C1 Esterase Inhibitor. [Updated 2018 Jul 31].
• 57. Baccioglu A, Kalpaklioglu AF. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema. Allergy 2014; 69: 493-4 (Abstract).

• Document Type: article